Infectious complications and immunotherapy: old pitfalls and new horizons

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Cai X, Zhan H, Ye Y et al. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases. Front. Genet. 12, 785153 (2021).
  Medline CASGoogle Scholar
• 2. Morelli T, Fujita K, Redelman-Sidi G, Elkington PT. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax 77(3), 304–311 (2022).
  MedlineGoogle Scholar
• 3. Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16(9), 563–580 (2019). • This paper is a very useful update on the management of the adverse effects of immune checkpoint inhibitors.
  Medline CASGoogle Scholar
• 4. Xie T, Zhang Z, Qi C et al. The inconsistent and inadequate reporting of immune-related adverse events in PD-1/PD-L1 inhibitors: a systematic review of randomized controlled clinical trials. Oncologist 26(12), e2239–e2246 (2021).
  Medline CASGoogle Scholar
• 5. Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin. Infect. Dis. 63(11), 1490–1493 (2016).
  MedlineGoogle Scholar
• 6. Ross JA, Komoda K, Pal S, Dickter J, Salgia R, Dadwal S. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 11(1), 21–27 (2022).
  Medline CASGoogle Scholar
• 7. Redelman-Sidi G, Michielin O, Cervera C et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin. Microbiol. Infect. 24(Suppl. 2), S95–S107 (2018).
  MedlineGoogle Scholar
• 8. Liu Z, Liu T, Zhang X et al. Opportunistic infections complicating immunotherapy for non-small cell lung cancer. Thorac. Cancer 11(6), 1689–1694 (2020).
  MedlineGoogle Scholar
• 9. Abers MS, Lionakis MS, Kontoyiannis DP. Checkpoint inhibition and infectious diseases: a good thing? Trends Mol. Med. 25(12), 1080–1093 (2019).
  Medline CASGoogle Scholar
• 10. Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. J. Dermatol. 45(1), 3–9 (2018). •• This review is a very useful update on the current knowledge of immune reconstitution inflammatory syndrome.
  MedlineGoogle Scholar
• 11. Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J. Thorac. Oncol. 11(12), 2238–2240 (2016).
  MedlineGoogle Scholar
• 12. Tezera LB, Bielecka MK, Ogongo P et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. eLife 9, e52668 (2020).
  Medline CASGoogle Scholar
• 13. Lasagna A, Zuccaro V, Sacchi P, Chiellino S, Bruno R, Pedrazzoli P. Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? Future Oncol. 17(13), 1577–1580 (2021).
  CASGoogle Scholar
• 14. Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146, 1193–1207 (2014).
  Medline CASGoogle Scholar
• 15. Lin X, Lu T, Li S et al. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study. Clin. Transl. Oncol. 23(2), 389–396 (2021).
  Medline CASGoogle Scholar
• 16. Jing Y, Chen X, Li K et al. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J. Immunother. Cancer 10(1), e003779 (2022).
  MedlineGoogle Scholar
• 17. Hwang JP, Feld JJ, Hammond SP et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J. Clin. Oncol. 38(31), 3698–3715 (2020).
  Medline CASGoogle Scholar
• 18. Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J. Immunother. Cancer. 7(1), 239 (2019).
  MedlineGoogle Scholar
• 19. Serra F, Cassaniti I, Lilleri D, Pedrazzoli P, Baldanti F, Lasagna A. Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors. Immunotherapy 14(6), 389–393 (2022).
  CASGoogle Scholar
• 20. Garcia de Moura R, Covre LP, Fantecelle CH et al. PD-1 blockade modulates functional activities of exhausted-like T cell in patients with cutaneous leishmaniasis. Front. Immunol. 12, 632667 (2021).
  MedlineGoogle Scholar